Eltrekibart
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LY3041658 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Eltrekibart (LY3041658) is a "septa-specific monoclonal antibody that neutralizes all seven ELR+ CXC chemokines (CXCL1-3 and CXCL5-8), thereby limiting signaling through CXCR1 and CXCR2".[1] It was tested in clinical trials for hidradenitis suppurativa.[1][2][3]
References
[edit]- ^ a b Fragoso, Natalie M.; Masson, Rahul; Gillenwater, T. Justin; Shi, Vivian Y.; Hsiao, Jennifer L. (4 July 2023). "Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies". Dermatology and Therapy. 13 (8): 1661–1697. doi:10.1007/s13555-023-00956-6. ISSN 2193-8210. PMC 10366071. PMID 37402031.
- ^ Boyles, Jeffrey S.; Beidler, Catherine B.; Strifler, Beth A.; Girard, Daniel S.; Druzina, Zhanna; Durbin, Jim D.; Swearingen, Michelle L.; Lee, Linda N.; Kikly, Kristine; Chintharlapalli, Sudhakar; Witcher, Derrick R. (1 January 2020). "Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody". mAbs. 12 (1). doi:10.1080/19420862.2020.1831880. PMC 7671035. PMID 33183151.
- ^ Tran, T.T.N.; Tran, Q.H.; Nguyen, Q.T.; Le, M.T.; Trinh, D.T.T.; Tran, V.H.; Thai, K.M. (3 October 2022). "LY3041658/ interleukin-8 complex structure as targets for IL-8 small molecule inhibitors discovery using a combination of in silico methods". SAR and QSAR in Environmental Research. 33 (10): 753–778. Bibcode:2022SQER...33..753T. doi:10.1080/1062936X.2022.2132536. PMID 36318662. S2CID 253257280.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |